Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) EBT (2020 - 2025)

RxSight (RXST) has disclosed EBT for 6 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 601.6% year-over-year to $29.7 million, compared with a TTM value of -$1000.0 through Dec 2025, up 100.0%, and an annual FY2025 reading of -$1000.0, up 100.0% over the prior year.
  • EBT was $29.7 million for Q4 2025 at RxSight, up from -$9.8 million in the prior quarter.
  • Across five years, EBT topped out at $29.7 million in Q4 2025 and bottomed at -$17.6 million in Q1 2022.
  • Average EBT over 5 years is -$9.6 million, with a median of -$12.1 million recorded in 2023.
  • The sharpest move saw EBT crashed 158.78% in 2022, then surged 601.6% in 2025.
  • Year by year, EBT stood at -$15.7 million in 2021, then increased by 0.88% to -$15.6 million in 2022, then surged by 41.08% to -$9.2 million in 2023, then soared by 35.56% to -$5.9 million in 2024, then soared by 601.6% to $29.7 million in 2025.
  • Business Quant data shows EBT for RXST at $29.7 million in Q4 2025, -$9.8 million in Q3 2025, and -$11.8 million in Q2 2025.